Drugs assessed by IQWiG

Introduction

Photo of taking medicine
PantherMedia / DepositNovic

A regulation that came into effect in Germany in early 2011 now stipulates that the added benefit of most medications containing new active ingredients be assessed as soon as they enter the market. Manufacturers initially set the prices for their new medications, but afterwards prices are based on the results of this assessment, called an “early benefit assessment pursuant to the Act on the Reform of the Market for Medicinal Products (AMNOG).”

When a medication is launched, the manufacturer is required to submit a dossier to the German Federal Joint Committee (G-BA) for early benefit assessment. This dossier must contain the results of all relevant studies on the new drug.

The Institute for Quality and Efficiency in Health Care (IQWiG, Germany) assesses this dossier on behalf of G-BA. Within three months, IQWiG issues a review evaluating the advantages and disadvantages of the new drug in comparison with an appropriate comparator treatment. G-BA and IQWiG both publish the final review.

You can find these drugs in the following table. An alphabetical list is available here.

Digestive system and metabolism

Click on the drug name for more information.

Table: Drugs assessed by IQWiG
Drug name Trade name Condition
Asfotase alfa Strensiq Hypophosphatasia
Dapagliflozin EU: Forxiga
U.S.: Farxiga
Type 2 diabetes
Dapagliflozin / metformin as a fixed-dose combination Xigduo Type 2 diabetes
Dulaglutide Trulicity Type 2 diabetes
Empagliflozin / linagliptin as a fixed-dose combination Glyxambi Type 2 diabetes
Ertugliflozin / sitagliptin as a fixed-dose combination Steglujan Type 2 diabetes
Glycopyrronium bromide Sialanar Chronic pathological drooling
Insulin degludec Tresiba Type 2 diabetes
Insulin degludec / liraglutide as a fixed-dose combination Xultophy Type 2 diabetes
Insulin glargine / lixisenatide as a fixed-dose combination Suliqua Type 2 diabetes
Naldemedine Rizmoic Opioid-induced constipation
Rolapitant EU: Varuby
U.S.: Varubi
Cancer-related nausea and vomiting
Saxagliptin / metformin as a fixed-dose combination Komboglyze Type 2 diabetes
Semaglutide Ozempic Type 2 diabetes
Sitagliptin Januvia, Xelevia Type 2 diabetes

Blood and blood production

Click on the drug name for more information.

Table: Drugs assessed by IQWiG
Drug name Trade name Condition
Damoctocog alfa pegol Jivi Hemophilia A
Emicizumab Hemlibra Hemophilia A
Fostamatinib Tavlesse Chronic immune thrombocytopenia
Lonoctocog alfa Afstyla Hemophilia A
Nonacog beta pegol Refixia Hemophilia B
Rurioctocog alfa pegol Adynovi Hemophilia A
Turoctocog alfa pegol Esperoct Hemophilia A

Heart and circulation

Click on the drug name for more information.

Table: Drugs assessed by IQWiG
Drug name Trade name Condition
Alirocumab Praluent Hypercholesterolemia and mixed dyslipidemia
Evolocumab Repatha Hypercholesterolemia and mixed dyslipidemia
Macitentan Opsumit Pulmonary arterial hypertension
Riociguat Adempas Pulmonary hypertension
Riociguat Adempas Pulmonary arterial hypertension

Skin and hair

Click on the drug name for more information.

Table: Drugs assessed by IQWiG
Drug name Trade name Condition
Dupilumab Dupixent Eczema
Ingenol mebutate Picato Actinic keratosis

Hormones

Click on the drug name for more information.

Table: Drugs assessed by IQWiG
Drug name Trade name Condition
Etelcalcetide Parsabiv Hyperparathyroidism
Hydrocortisone Alkindi Adrenal insufficiency

Infections

Click on the drug name for more information.

Table: Drugs assessed by IQWiG
Drug name Trade name Condition
Bezlotoxumab Zinplava Costridium difficile infections
Bictegravir / emtricitabine / tenofovir alafenamide as a fixed-dose combination Biktarvy HIV
Darunavir combination Symtuza HIV
Dolutegravir Tivicay HIV
Dolutegravir / rilpivirine as a fixed-dose combination Juluca HIV
Doravirine Pifeltro HIV
Doravirine / lamivudine / tenofovir disoproxil fumarate as a fixed-dose combination Delstrigo HIV
Elbasvir / grazoprevir Zepatier Hepatitis C
Elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide as a fixed-dose combination Genvoya HIV
Elvitegravir / cobicistat / emtricitabine / tenofovir disoproxil as a fixed-dose combination Stribild HIV in teenagers
Glecaprevir / pibrentasvir as a fixed-dose combination Maviret Chronic hepatitis C
Ledipasvir / sofosbuvir as a fixed-dose combination Harvoni Chronic hepatitis C in teenagers
Ravulizumab Ultomiris Paroxysmal nocturnal hemoglobinuria
Sofosbuvir Sovaldi Chronic hepatitis C
Sofosbuvir / velpatasvir as a fixed-dose combination Epclusa Chronic hepatitis C
Sofosbuvir / velpatasvir / voxilaprevir as a fixed-dose combination Vosevi Chronic hepatitis C
Tenofovir alafenamide Vemlidy Chronic hepatitis B

Cancer and the immune system

Click on the drug name for more information.

Table: Drugs assessed by IQWiG
Drug name Trade name Condition
Abiraterone acetate Zytiga Metastatic prostate cancer
Abemaciclib and aromatase inhibitor EU: Verzenios
U.S.: Verzenio
Advanced breast cancer
Abemaciclib and fulvestrant EU: Verzenios
U.S.: Verzenio
Advanced breast cancer
Alectinib Alecensa Advanced lung cancer
Apalutamide Erleada Metastatic prostate cancer
Apremilast Otezla Behçet's disease
Atezolizumab Tecentriq Advanced lung cancer
Atezolizumab Tecentriq Bladder cancer (urothelial carcinoma)
Avelumab Bavencio Advanced renal cell cancer
Axitinib Inlyta Advanced renal cell cancer
Baricitinib Olumiant Rheumatoid arthritis
Belimumab Benlysta Systemic lupus erythematosus in children and teenagers
Binimetinib and encorafenib (combination) Mektovi / Braftovi Advanced melanoma
Brigatinib Alunbrig Advanced non-small-cell lung cancer
Bosutinib Bosulif Chronic myeloid leukemia
Cabozantinib Cabometyx Advanced hepatocellular carcinoma
Cabozantinib Cabometyx Avanced renal cell cancer
Carfilzomib Kyprolis Multiple myeloma
Cemiplimab Libtayo Advanced non-melanoma skin cancer
Ceritinib Zykadia Advanced lung cancer
Cladribine Mavenclad Multiple sclerosis
Crizotinib Xalkori Advanced lung cancer
Dabrafenib and trametinib (combination) Tafinlar / Mekinist Melanoma
Dacomitinib Vizimpro Advanced lung cancer
Daratumumab Darzalex Multiple myeloma
Darolutamide Nubeqa Prostate cancer
Dolutegravir / lamivudine Dovato HIV
Durvalumab Imfinzi Advanced lung cancer
Elotuzumab Empliciti Multiple myeloma
Encorafenib Braftovi Metastatic colorectal cancer
Enzalutamide Xtandi Metastatic prostate cancer
Eribulin Halaven Liposarcoma
Fingolimod Gilenya Multiple sclerosis
Guselkumab Tremfya Psoriasis
Ibrutinib Imbruvica Chronic lymphocytic leukemia
Ibrutinib Imbruvica Waldenström's macroglobulinemia
Idelalisib Zydelig Chronic lymphocytic leukemia
Ipilimumab Yervoy Melanoma
Ipilimumab combined with nivolumab Yervoy / Opdivo Advanced renal cell cancer
Ixekizumab Taltz Psoriasis
Larotrectinib Vitrakvi Advanced tumor
Lenvatinib EU: Kisplyx
U.S.: Lenvima
Advanced renal cell cancer
Lenvatinib Lenvima Advanced thyroid cancer
Lenvatinib Lenvima Hepatocellular carcinoma (liver cancer)
Lorlatinib EU: Lorviqua
U.S.: Lorbrena
Advanced lung cancer
Neratinib Nerlynx Breast cancer
Nintedanib Ofev Idiopathic pulmonary fibrosis
Niraparib Zejula Ovarian cancer
Nivolumab Opdivo Head and neck cancer
Nivolumab Opdivo Hodgkin's lymphoma
Nivolumab Opdivo Melanoma
Nivolumab Opdivo Advanced bladder cancer (urothelial carcinoma)
Ocrelizumab Ocrevus Multiple sclerosis
Olaparib Lynparza Advanced breast cancer
Olaparib Lynparza Ovarian cancer
Osimertinib Tagrisso Advanced lung cancer with T790M mutation
Osimertinib Tagrisso Advanced lung cancer with activating EGFR mutations
Palbociclib Ibrance Advanced breast cancer
Pembrolizumab Keytruda Advanced lung cancer
Pembrolizumab in combination with chemotherapy Keytruda Advanced lung cancer
Pembrolizumab Keytruda Advanced bladder cancer (urothelial carcinoma)
Pembrolizumab Keytruda Advanced renal cell carcinoma
Pembrolizumab Keytruda Head and neck cancer
Pembrolizumab Keytruda Hodgkin's lymphoma
Pembrolizumab Keytruda Melanoma
Pertuzumab Perjeta Breast cancer
Pomalidomide EU: Imnovid
U.S.: Pomalyst
Multiple myeloma
Radium-223 dichloride Xofigo Advanced prostate cancer
Ramucirumab Cyramza Advanced liver cancer
Ramucirumab Cyramza Advanced lung cancer
Ribociclib Kisqali Advanced breast cancer
Risankizumab Skyrizi Psoriasis
Ropeginterferon alfa-2b Besremi Polycythemia vera
Rucaparib Rubraca Advanced ovarian cancer
Sarilumab Kevzara Rheumatoid arthritis
Secukinumab Cosentyx Psoriasis
Sonidegib Odomzo Non-melanoma skin cancer
Tildrakizumab EU: Ilumetri
U.S.: Ilumya
Psoriasis
Tivozanib Fotivda Advanced renal cell cancer
Trametinib / dabrafenib Mekinist / Tafinlar Advanced lung cancer
Tofacitinib Xeljanz Psoriatic arthritis
Tofacitinib Xeljanz Rheumatoid arthritis
Tofacitinib Xeljanz Ulcerative colitis
Trifluridine / tipiracil Lonsurf Advanced gastric cancer
Trifluridine / tipiracil Lonsurf Metastatic colorectal cancer
Upadacitinib Rinvoq Rheumatoid arthritis
Vandetanib Caprelsa Aggressive thyroid cancer
Venetoclax EU: Venclyxto
U.S.: Venclexta
Chronic lymphocytic leukemia (CLL)

Brain and nervous system

Click on the drug name for more information.

Table: Drugs assessed by IQWiG
Drug name Trade name Condition
Brivaracetam Briviact Epilepsy
Cannabis sativa Sativex Spasticity in multiple sclerosis
Cariprazin Reagila Schizophrenia
Dimethyl fumarate Skilarence Psoriasis
Erenumab Aimovig Prevention of migraine
Fremanezumab Ajovy Migraine
Galcanezumab Emgality Prevention of migraine
Lisdexamfetamine EU: Elvanse / Elvanse Adult
U.S.: Vyvanse
ADHD
Melatonin Slenyto Insomnia
Nalmefene Selincro Alcohol dependency
Opicapone Ongentys Parkinson's disease
Perampanel Fycompa Epilepsy
Siponimod Mayzent Multiple sclerosis
Solriamfetol Sunosi Narcolepsy

Lungs and breathing

Click on the drug name for more information.

Table: Drugs assessed by IQWiG
Drug name Trade name Condition
Benralizumab Fasenra Severe asthma
Dupilumab Dupixent Chronic rhinosinusitis with nasal
Dupilumab Dupixent Severe asthma
Fluticasone furoate / umeclidinium / vilanterol as a fixed-dose combination Trelegy ellipta Chronic obstructive pulmonary disease (COPD)
Ivacaftor Kalydeco Cystic fibrosis
Ivacaftor and the fixed-dose combination tezacaftor/ivacaftor Kalydeco/Symkevi Cystic fibrosis
Lumacaftor / ivacaftor as a fixed-dose combination Orkambi Cystic fibrosis
Mepolizumab Nucala Severe asthma
Reslizumab EU: Cinqaero
U.S.: Cinqair
Severe asthma
Tezacaftor / ivacaftor as a fixed-dose combination Symkevi Cystic fibrosis

Sensory organs

Click on the drug name for more information.

Table: Drugs assessed by IQWiG
Drug name Trade name Condition
Ocriplasmin Jetrea Vitreomacular traction

Other

Click on the drug name for more information.

Table: Drugs assessed by IQWiG
Drug name Trade name Condition
Andexanet alfa Ondexxya (EU), Andexxa (U.S.) Major bleeding
Patiromer Veltassa Hyperkalemia

IQWiG health information is written with the aim of helping people understand the advantages and disadvantages of the main treatment options and health care services.

Because IQWiG is a German institute, some of the information provided here is specific to the German health care system. The suitability of any of the described options in an individual case can be determined by talking to a doctor. informedhealth.org can provide support for talks with doctors and other medical professionals, but cannot replace them. We do not offer individual consultations.

Our information is based on the results of good-quality studies. It is written by a team of health care professionals, scientists and editors, and reviewed by external experts. You can find a detailed description of how our health information is produced and updated in our methods.

Comment on this page

What would you like to share with us?

We welcome any feedback and ideas. We will review, but not publish, your ratings and comments. Your information will of course be treated confidentially. Fields marked with an asterisk (*) are required fields.

Please note that we do not provide individual advice on matters of health. You can read about where to find help and support in Germany in our information “How can I find self-help groups and information centers?

Updated on December 28, 2020
Next planned update: 2021

Authors/Publishers:

Institute for Quality and Efficiency in Health Care (IQWiG, Germany)

How we keep you informed

Follow us on Twitter or subscribe to our newsletter or newsfeed. You can find all of our films online on YouTube.